Bradley Leibovich
Overview
Explore the profile of Bradley Leibovich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
522
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Myers A, Briganti A, Leibovich B, Lerner S, Moschini M, Roupret M, et al.
Eur Urol Oncol
. 2023 Nov;
7(3):412-420.
PMID: 37980250
Context: Lymphadenectomy during surgery for genitourinary malignancies has varying benefits. Objective: To review contemporary evidence on lymph node dissection in genitourinary cancers. Evidence Acquisition: We performed a collaborative review to...
2.
Eckel-Passow J, Yan H, Kosel M, Serie D, Decker P, Jenkins R, et al.
BMC Urol
. 2020 Oct;
20(1):173.
PMID: 33121461
Background: The four most commonly-mutated genes in clear cell renal cell carcinoma (ccRCC) tumors are BAP1, PBRM1, SETD2 and VHL. And, there are currently 14 known RCC germline variants that...
3.
Dubey D, Wilson M, Clarkson B, Giannini C, Gandhi M, Cheville J, et al.
JAMA Neurol
. 2020 Aug;
77(11):1420-1429.
PMID: 32744608
Importance: Recognizing the presenting and immunopathological features of Kelch-like protein-11 immunoglobulin G seropositive (KLHL11 IgG+) patients may aid in early diagnosis and management. Objective: To describe expanding neurologic phenotype, cancer...
4.
Ziegelmann M, Joseph J, Glasgow A, Tyson M, Pak R, Gazelka H, et al.
Am J Surg
. 2019 Dec;
220(2):499-504.
PMID: 31831158
Background: We developed evidence-based guidelines for postoperative opioid prescribing after urologic surgery and assessed changes in prescribing after implementation. Methods: Prescribing data for adults who underwent 21 urologic procedures were...
5.
Stephenson A, Eggener S, Bass E, Chelnick D, Daneshmand S, Feldman D, et al.
J Urol
. 2019 May;
202(2):272-281.
PMID: 31059667
Purpose: Testis cancer is the most common solid malignancy in young males. The purpose of this guideline is to provide a useful reference on the effective evidence-based treatment of early...
6.
Shenoy N, Bhagat T, Cheville J, Lohse C, Bhattacharyya S, Tischer A, et al.
J Clin Invest
. 2019 Feb;
129(4):1612-1625.
PMID: 30702441
Although clear cell renal cell carcinoma (ccRCC) has been shown to result in widespread aberrant cytosine methylation and loss of 5-hydroxymethylcytosine (5hmC), the prognostic impact and therapeutic targeting of this...
7.
Toussi A, Agarwal D, Leibovich B, Potretzke A
Int Braz J Urol
. 2019 Jan;
45(3):640.
PMID: 30620159
Introduction: Metastasis-directed therapy of small solitary foci of metastatic renal cell carcinoma has been associated with improved survival. Percutaneous resection of tumors in the upper tract urinary system has been...
8.
Schmit C, Matsumoto J, Yost K, Alexander A, Ness L, Kurup A, et al.
Abdom Radiol (NY)
. 2018 Jul;
44(1):304-309.
PMID: 30054687
Purpose: To determine whether a 3D printed model improves patients' understanding of renal cryoablation and the involved anatomy. Methods: This prospective study included 25 control patients, who received standard of...
9.
Wallis C, Klaassen Z, Bhindi B, Ye X, Chandrasekar T, Farrell A, et al.
Eur Urol
. 2018 Apr;
74(3):309-321.
PMID: 29656851
Context: In the last decade, there has been a proliferation of treatment options for metastatic renal cell carcinoma (mRCC). However, direct comparative data are lacking for most of these agents....
10.
Tan W, Boorjian S, Advani P, Farmer S, Lohse C, Cheville J, et al.
Clin Genitourin Cancer
. 2015 May;
13(5):476-84.
PMID: 25981333
Objective: Bladder cancer has the sixth highest incidence in the United States. Treatment of metastatic bladder cancer is difficult, and mortality is certain. There are certain pathways in cancer growth...